Bayer and DelSiTech announce Collaboration and Technology License Agreement

Bayer and DelSiTech have issued a joint announcement regarding the signing of a Collaboration and Technology License Agreement.

The agreement will involve the global application of the Silica Matrix drug delivery system, developed by DelSiTech, to various Bayer ophthalmology compounds.

"Successful ocular drug delivery is one of the biggest challenges in developing novel drug therapies for ophthalmic diseases.This agreement will support our work on innovative treatment options for a range of different eye diseases,” Bayer AG Pharmaceuticals head of drug discovery Andreas Busch said. "This partnership with DelSiTech underlines Bayer's continued commitment to leverage collaborations on cutting edge science in ophthalmology with the aim to improve the quality of life for patients."

According to the newly signed agreement, DelSiTech could receive possible milestone payments.

"This partnership with Bayer is an exciting development for DelSiTech,” DelsiTech CEO Dr. Lasse Leino said. “It follows an already successful and long-lasting collaboration with Bayer in which our Silica Matrix technology has been evaluated. We are very pleased that Bayer has chosen DelSiTech as its technology partner for ophthalmology drug delivery. It illustrates the great potential of biodegradable silica material in demanding drug delivery applications."